In a recent podcast, experts Tina Cascone, Christina Baik, and David Planchard explored innovative, data-driven treatment methods for patients with EGFR-mutation positive non-small cell lung cancer (NSCLC). The discussion focuses on applying evidence across various stages of the disease continuum.
The podcast is designed to enhance the listener”s understanding of the treatment landscape for EGFR-mutant NSCLC, emphasizing practical applications and recent advances in therapy.
Tina Cascone, MD, PhD, serves as the chair of the session. She holds the position of Associate Professor and Physician-Scientist at the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. Her affiliations with various pharmaceutical companies, including AstraZeneca and Bristol Myers Squibb, highlight her active role in the field.
Joining her is Christina Baik, MD, MPH, who specializes in thoracic and head and neck medical oncology at the Fred Hutchinson Cancer Center and the University of Washington School of Medicine in Seattle. She has received support from several major pharmaceutical companies for her research and advisory roles.
David Planchard, MD, PhD, leads the thoracic group in the Department of Medical Oncology at the Institut Gustave Roussy in Villejuif, France. His extensive experience includes consulting and research funding from various industry leaders in oncology.
This educational activity is funded by a grant from AstraZeneca, emphasizing the collaborative effort between academia and the pharmaceutical industry to advance cancer treatment.
Participants in this educational session are encouraged to consult current prescribing information for any discussed therapies, as the podcast may include references to unapproved or investigational drug uses. The insights shared aim to inform healthcare professionals about the latest strategies for addressing the challenges posed by EGFR-mutant NSCLC, particularly regarding treatment resistance.
The podcast is set to be available for listeners from October 24, 2025, and will remain accessible until October 24, 2026, allowing ample time for healthcare professionals to enhance their knowledge in this critical area of oncology.
For more details on the adjuvant treatment of early-stage EGFR-mutant NSCLC and strategies targeting resistance mechanisms in metastatic disease, listeners can visit the provided link.
